Resistant and severe hypertension represent a growing global health burden and are associated with a markedly increased risk of cardiovascular, renal, and ...

When the heart begins to fail, the body does everything in its power to fix the situation. But sometimes, those compensatory mechanisms ultimately do more harm than good. Such is the case with the ...

A highly selective aldosterone synthase inhibitor, lorundrostat, showed promise for blood pressure reduction in a double-blind randomized phase IIb trial. Participants with uncontrolled and otherwise ...

Please provide your email address to receive an email when new articles are posted on . Once-daily lorundrostat, an aldosterone synthase inhibitor, significantly decreased automated office systolic BP ...

Empirical and theoretical studies can be distinguished among the areas of investigation of the renin-angiotensin-aldosterone system (RAAS) and its relationship with the development of cardiovascular ...

Diabetics aided by spironolactone with ACE inhibitors, angiotensin receptor. The renin-angiotensin-aldosterone system (RAAS) is a well-known regulator of BP, and angiotensin II (AII) plays the primary ...

Lorundrostat (Mineralys Therapeutics), a novel aldosterone synthase inhibitor, can substantially lower blood pressure in patients with uncontrolled and treatment-resistant hypertension, according to ...

Lorundrostat treatment led to greater reductions in 24-hour mean blood pressure compared with placebo in trial participants with uncontrolled and treatment-resistant hypertension. Lorundrostat, a ...

Aldosterone is a hormone that helps regulate sodium and potassium levels in the blood. Hyperaldosteronism and hypoaldosteronism are conditions involving abnormal aldosterone levels. The adrenal glands ...

The George Institute for Global Health is thrilled to congratulate doctoral researcher Dr Lauren Heath on receiving a ...